HAIC Combined With Sintilimab Plus Bevacizumab Biosimilar for Advanced Hepatocellular Carcinoma (TASK-03)

This study is testing a combination of hepatic arterial infusion chemotherapy (HAIC — high-dose chemo delivered directly to the liver), sintilimab (an immunotherapy), and bevacizumab biosimilar (a drug that blocks tumor blood vessel growth) in patients with advanced liver cancer (hepatocellular carcinoma, HCC) who have not yet received systemic treatment. **You may be eligible if...** - You are 18 or older - You have confirmed HCC at an advanced (Barcelona Stage C) or intermediate (Stage B) stage not eligible for surgery or local treatment - You have not received any prior systemic therapy for liver cancer - You have at least one measurable tumor, adequate liver function (Child-Pugh score 5–7), and ECOG performance status 0–2 - If you have hepatitis B, your viral load is below 100 IU/mL and you are on antiviral therapy **You may NOT be eligible if...** - You are on a liver transplant waiting list or have advanced liver disease - You have had a stroke, serious blood clot, or pulmonary embolism in the past 6 months - You have received prior systemic, endocrine, or immune therapy for HCC - You have previously been treated with HAIC Talk to your doctor to see if this trial is right for you.